Targeting Ovarian Carcinoma with TSP-1:CD47 Antagonist TAX2 Activates Anti-Tumor Immunity
Authors:
- Albin JeanneAJAlbin Jeanne
- Thomas SarazinTSThomas Sarazin
- Magalie CharléMCMagalie Charlé
- Catherine MoaliCMCatherine Moali
- Caroline FichelCFCaroline Fichel
- Camille Boulagnon-RombiCBCamille Boulagnon-Rombi
- Maïté CallewaertMCMaïté Callewaert
- Marie-Christine AndryMAMarie-Christine Andry
- Eric DiesisEDEric Diesis
- Frédéric DelolmeFDFrédéric Delolme
- Damien RioultDRDamien Rioult
- Stéphane DedieuStéphane Dedieu
Open Access
Abstract
TAX2 peptide is a cyclic peptide that acts as an orthosteric antagonist for thrombospondin-1 (TSP-1) interaction with CD47. TAX2 was first described for its anti-angiogenic activities and showed anti-cancer efficacy in numerous preclinical models. Here, we aimed at providing an extensive molecular characterization of TAX2 mode of action, while evaluating its potential in ovarian cancer therapy. Multidisciplinary approaches were used to qualify a TAX2 drug candidate in terms of stability, solubility and potency. Then, efficacy studies, together with benchmark experiments, were performed in relevant mouse models of ovarian carcinoma. TAX2 peptide appears to be stable and soluble in clinically relevant solvents, while displaying a favorable safety profile. Moreover, clinical data mining allowed for the identification of TSP-1 as a relevant pharmacological target in ovarian cancer. In mice, TAX2 therapy inhibits ovarian tumor growth and metastatic dissemination, while activating anti-cancer adaptive immunity. Interestingly, TAX2 also synergizes when administered in combination with anti-PD-1 immune checkpoint inhibitiors. Altogether, our data expose TAX2 as an optimized candidate with advanced preclinical characterization. Using relevant syngeneic ovarian carcinoma models, we highlighted TAX2’s ability to convert poorly immunogenic tumors into ones displaying effective anti-tumor T-cell immunity.Keywords
Funding Information
- Université de Reims Champagne-Ardenne (-)
- Centre National de la Recherche Scientifique (-)
- Société d'Accélération du Transfert de Technologies (-)
- Apmonia Therapeutics (-)
- Région Grand-Est (-)
This publication has 56 references indexed in Scilit:
- SurvExpress: An Online Biomarker Validation Tool and Database for Cancer Gene Expression Data Using Survival AnalysisPLOS ONE, 2013
- Thrombospondin-1 is a CD47-dependent endogenous inhibitor of hydrogen sulfide signaling in T cell activationMatrix Biology, 2013
- Sequence‐specific determination of protein and peptide concentrations by absorbance at 205 nmProtein Science, 2013
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics DataCancer Discovery, 2012
- Radioprotection in Normal Tissue and Delayed Tumor Growth by Blockade of CD47 SignalingScience Translational Medicine, 2009
- Lysophosphatidic acid stimulates cell migration, invasion, and colony formation as well as tumorigenesis/metastasis of mouse ovarian cancer in immunocompetent miceMolecular Cancer Therapeutics, 2009
- Human thrombospondin’s (TSP-1) C-terminal domain opens to interact with the CD-47 receptor: A molecular modeling studyArchives of Biochemistry and Biophysics, 2008
- Thrombospondins: from structure to therapeuticsCellular and Molecular Life Sciences, 2008
- Development and application of high throughput plasma stability assay for drug discoveryInternational Journal of Pharmaceutics, 2005
- Experimental Design for Analysis of Complex Kinetics Using Surface Plasmon ResonanceMethods, 2000